Tim Boire, CEO and co-founder of VenoStent, shares his company's roadmap on this week's episode of the Houston Innovators Podcast. Photo via LinkedIn

Commercializing a health tech innovation is a long game — fraught with regulatory obstacles, cyclical rounds of funding, and continuous improvement — all fueled by the desire to enhance treatment and save lives.

That's Tim Boire's plan. And it's a thorough one at that. On this week's episode of the Houston Innovators Podcast, Boire — president and CEO of VenoStent, a medical device startup that’s designing a unique material for hemodialysis patients — shares his roadmap for his company.

"We believe we can be pioneers of a paradigm shift in vascular surgery — to not just treat problems after they've already occurred, but actually prevent them from occurring in the first place," he says in the episode.

VenoStent's most recent hurdle cleared is closing a $16 million series A round of venture funding. Two Charleston, South Carolina-based firms — Good Growth Capital and IAG Capital Partners — led the round. The TMC Venture Fund also contributed.

Now, VenoStent is headed for a 200-patient trial in the United States, with an ultimate goal of product launch in 2026. The company's unique medical device is a bioabsorbable wrap that reduces vein collapse by providing mechanical support and promoting outward vein growth.

Boire had the idea for VenoStend when he was completing his PhD at Vanderbilt University. He completed the program, and then joined the HealthWildcatters accelerator in 2017 in Dallas. After that, Boire and his co-founder, Geoff Lucks, decided to take the leap and move to Houston to join JLABS at TMC. The rest, as they say, is history.

“Houston’s been a great place to hire,” Boire says. “We've been I think very fortunate to find our employees who are stellar, true believers in the technology — amazing engineers, and amazing people.”

And, of course, Boire has a plan to continue this hiring success. He says the goal is to grow to a team of 16 by the end of the year. Marketing and sales roles will likely be filled in 2025 ahead of product launch.

“When we think about what our mission is at VenoStent, it’s to ultimately improve patient care — and we are very passionate about this specific problem that patients experience and go through,” Boire says.

“That's what drives everything we're doing as a company to improve quality and length of life for patients who have chronic kidney disease that progresses to a point where they need dialysis to sustain life," he continues. "We believe that we can become the standard care for vascular surgery starting with hemodialysis access."

As VenoStent's trials and growth goes according to plan, Boire says this product can be used for other implications.

Boire shares more on his grand plan, plus how he weathered the storm that is fundraising at a time where so much venture capital activity has slowed. Listen to the interview here — or wherever you stream your podcasts — and subscribe for weekly episodes.

7 Hills Pharma, an innovative immunotherapy company, was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Houston immunotherapy company to use $13.5M grant to further develop cancer treatments

future of pharma

Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.

“My father’s first job was to take care of the pilgrims,” recalls Marathi.

It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.

“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.

Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas.

Launched in 2016, 7 Hills Pharma is working to develop drugs that can overcome the all-too-common problem of immunotherapy resistance. Thanks to the Nobel Prize-winning work of Jim Allison in the realm of immuno-oncology, the field was “very hot” at the time, says Marathi, particularly in Houston.

So what has 7 Hills developed? Oral small molecules that activate integrins — the receptors that allow cells to bind to one another — allowing for the cell-to-cell interactions that create a successful immune response to immune checkpoint inhibitors such as Yervoy. In other words, they have created capsules that increase the effectiveness of drugs that allow the body’s own immune response to fight cancers.

But that’s not all. Tests have shown that the same discovery, called alintegimod, can also augment the effectiveness of vaccines. The pill, which co-founder and co-inventor Peter Vanderslice calls “a beautiful way to amplify the vaccines,” can potentially be applied to anything from influenza to coronavirus.

Their greatest challenge, says Vanderslice, is the very fact that the technology is so novel.

“Most large pharmas are very risk averse,” he explains. “They only want to do ‘me-too’ kinds of drugs.”

7 Hills Pharma is the third company Marathi, both a PhD and an MBA, has helped to found based on technology he co-invented. Vanderslice is director of the molecular cardiology research laboratories at The Texas Heart Institute.

“It’s very much a homegrown company,” Marathi says.

And a small one, at least for now. Working out of JLabs@TMC, the full-time team is currently just Marathi and Siddhartha De, the senior director of development. Marathi convinced De to transplant himself and his family from India for the purpose of assisting 7 Hills with preparing its drugs for clinical readiness.

The CPRIT funds will allow 7 Hills Pharma to hire several long-time team members full-time and with benefits.

“The bringing of talent and bringing of technology to TMC and what was born at Texas Heart Institute is rather remarkable,” says Rob Bent, the company’s director of operations.

The next step for 7 Hills Pharma is a Phase Ib/IIa clinical trial in patients with treatment-resistant solid tumors. And the team just finalized the deck that will help raise another $10 million to $250 million in the company’s series A. And hopefully sooner rather than later, a new set of medical pilgrims will be thanking 7 Hill Pharma for its care.

It's a busy month in Houston. Luis Alvarez/Getty Images

10+ can't-miss Houston business and innovation events for March

Where to be

Editor's note: SXSW has been canceled due to the coronavirus since the publishing on this events roundup. The original version of this article is below.

March is a busy month for Houston in general — but especially when it comes to innovation. The inaugural Houston Tech Rodeo starts out the month and the Rice Business Plan Competition closes out March in a few weeks — and the interactive weekend at SXSW falls right in the middle of the month for those planning the trip to Austin.

But for the Houston innovators in the energy industry, March got a little less busy when CERAWeek by IHS Markit was canceled due to the growing threat of the coronavirus, or COVID19.

Should any other events below have that same fate, this article will be updated.

March 2-6 — Houston Tech Rodeo

A week full of events, the Tech Rodeo is made up of over 30 innovation events across Houston. These are InnovationMap's picks for what to attend during the week. For a complete list of the events (most of which are free), head to the website.

Details: The event is from Monday, March 2, to Friday, March 6 across Houston. Learn more.

March 5 — Space Center Houston's Thought Leader Series: Designing for Human Performance

Learn how human factors engineering relates to spacecraft and spacesuit design while celebrating Women's History Month and the 20th anniversary of the International Space Station. Speakers include Celena Dopart, human factors engineer for Starliner at Boeing, and Katie Spira, NASA flight controller.

Details: The event is at 7 pm on Thursday, March 5, at Space Center Houston (1601 E NASA Pkwy). Learn more.

March 6 — Premier Talks: Women in Innovation & Technology 

Join this panel of accomplished women as they discuss the importance of being a woman in the current workforce and leading among your peers. Be empowered to self-evaluate, inspire those around you, and raise the bar on your professional goals. Discuss the challenges women face in a male dominated technology workforce and why it is important to take the limits off of your thinking.

Details: The event is from 9:15 to 11 am on Friday, March 6, at GA Houston (1301 Fannin St, Floor 21). Learn more.

March 6 — The Greater Houston Partnership’s Rise to the Top

Celebrating International Women's Day, the Greater Houston Partnership and the Partnership's Women's Business Alliance brings the Rise to the Top event. Expect a keynote address from Gretchen Watkins, president atShell Oil Company and executive vice president at Global Unconventionals, Shell Oil Company, and candid conversations from a panel of female executives discussing the challenges and triumphs of succeeding as a woman in today's business environment.

Details: The event is from 10:30 am to 1:30 pm on Friday, March 6, at Hilton Americas (1600 Lamar St.). Learn more.

March 10 — Equinor & Techstars Energy Accelerator Meet & Greet

If you're an energy-focused startup, don't miss this info session with the Equinor & Techstars Energy Accelerator, which is visiting Houston and looking for the 10 best energy companies for its next cohort.

Details: The event is from 6 to 9 pm on Monday, March 10, at The Ion (1301 Fannin Street, Suite 2440). Learn more.

March 10-11 — Energy 2.0: Equality, Environment, and the New Economy

Join over 100,000 people taking part in Energy 2.0 2020; an innovative experience that addresses new frontiers in the energy industry where business, workforce, environment, innovation, and policy intersect. Spread across multiple locations and continents, corporate watch sites around the globe, and simulcast online, Energy 2.0 brings energy professionals and a diverse mix of experts across various disciplines together for learning and networking opportunities.

Details: The event is from Monday, March 10, to Tuesday, March 11, online and at The Westin Houston, Memorial City (945 Gessner Rd.). Learn more.

March 12 — Lunch n' Learn: In Today's Market - Do Patents Even Matter?

Inventors and business professionals are asked to review the claims of their patent application before it is filed. This step is THE critical step that is supposed to ensure that the claims will protect their invention. The decision you make here determines if you will be part of the 97 percent of all patents that never recoup the cost of filing them.

Details: The event is from noon to 1:30 pm on Wednesday, March 12, at The Ion (1301 Fannin Street, Suite 2440). Learn more.

March 19 — Science First: How 3D Printing is Reshaping the Future of Healthcare

Technology is evolving faster than ever – and advancements in 3D printing could revolutionize the delivery of healthcare products and solutions to change the trajectory of health for humanity.

Details: The event is from 11:30 am to 2 pm on Wednesday, March 19, at JLABS @ TMC (2450 Holcombe Blvd.). Learn more.

March 24 — How to Form a Micro VC Fund Workshop at Mercury Fund

Welcoming all angels, previous founders, MBA students, aspiring and current venture capitalists that are interested in learning more about the basic essentials for starting a small venture fund. Speakers are Blair Garrou of Mercury Fund and Justin LaPoten of BADR Investments.

Details: The event is from 10 to 11 am on Tuesday, March 24, at Mercury Fund (3737 Buffalo Speedway, #Suite 1750). Learn more.

March 25 — 2020 H. Albert Napier Rice Launch Challenge - Startup Competition

The H. Albert Napier Rice Launch Challenge Startup Competition is Rice's newest entrepreneurship competition, awarding over $60,000 in prize money to Rice-affiliated teams. Students and alumni enter business ideas (high growth ventures or small business ideas) to compete.

Details: The event is from 6 to 9 pm on Wednesday, March 25, at Liu Idea Lab For Innovation & Entrepreneurship (Rice University - Cambridge Office Building). Learn more.

March 26 — T3CH Workshop: Grow With Google "Using Data to Drive Business Growth"

In this T3CH workshop, you'll learn best practices on data-driven decision making; and get practical guidance on how to find and analyze trends regarding online customer engagement with your business, so you can turn those insights into well-informed, actionable decisions.

Details: The event is from noon to 1 pm on Thursday, March 26, at Impact Hub Houston @ The Cannon Post Oak (675 Bering Drive, #200). Learn more.

March 26-28 — Rice Business Plan Competition

The event — dubbed the "world's richest and largest student startup competition" — begins later this month. The Rice Business Plan Competition will host 42 student teams from all over the world. The three-day contest consists of pitches, judging, and a closing banquet where the winners are revealed.

Details: The event is from Thursday, March 26, to Saturday, March 28, at Rice University and the Hilton Americas. Learn more.

Check out these panels, networking meetups, and more. Getty Images

10+ can't-miss Houston business and innovation events for February

Where to be

Despite the short month, Houston will play host to tons of innovation networking, panel, and meetup events throughout the month of February. And, it's a leap year, so take that as an opportunity to jump into the startup ecosystim in town.

If you know of innovation-focused events for this month or next, email me at natalie@innovationmap.com with the details and subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.

February 4 — How AI Can Boost Your Business with Ryan Shirzadi of Tekrevol

How can artificial intelligence help grow your business? Specifically, Ryan Shirzadi of Tekrevol will be covering the social impacts, industries affected, why you need an AI strategy, and how AI can help small businesses grow. Networking will follow the discussion and pizza will be provided by Tekrevol.

Details: The event is from 6 to 7:30 pm on Tuesday, February 4, at Station Houston (1301 Fannin Street, Suite 2440). Learn more.

February 5 — Meet and Greet with Pat Matthews, CEO & Founder of Active Capital

Meet Active Capital's founder and CEO, Pat Matthews. Rakesh Agrawal, founder and CEO of Snapstream, will interview Matthews followed up by an open Q&A and conversation with the audience.

Details: The event is from 5:30 to 6:45 pm on Wednesday, February 5, at WeWork (708 Main Street, 3rd Floor). Learn more.

February 5 — Houston Social Entrepreneurship Meetup

The meetup brings together like-minded individuals from the nonprofit, social enterprise, impact investing, technology and many other fields to understand the concept of social entrepreneurship and be inspired to find new ways to tackle local social issues. At each meetup, you'll get an intro to social entrepreneurship, hear from a social entrepreneur in Houston, and network with other changemakers from across the entrepreneur ecosystem.

Details: The event is from 5:30 to 7:30 pm on Wednesday, February 5, at Impact Hub Houston @ The Cannon Downtown (1801 Main St., 13th Floor). Learn more.

February 6 — Fail Forward presented by Frost Bank

Join BakerRipley and Frost Bank for an evening of #FailForward fun and get real, behind-the-scenes stories straight from entrepreneurs on the challenges they faced trying to access and raise funding for their small business or startups.

Details: The event is from 6 to 8 pm on Thursday, February 6, at BakerRipley Center (4450 Harrisburg Blvd.). Learn more.

February 12 — The Impact of AI on Automation and the Future of the Workforce

Technology and innovation are rapidly changing how we do and think about work. This panel event seeks to bring together respected leaders in the corporate and entrepreneurial worlds to have meaningful conversations on AI, automation and the future of workforce.

Details: The event is from 6:30 to 9 pm on Wednesday, February 12, at GA Houston (1301 Fannin St, Floor 21). Learn more.

February 13 — Female Founders Breakfast with Baker Botts and The Artemis Fund

Baker Botts L.L.P. and The Artemis Fund have come together to bring you a breakfast panel discussion on how a good corporate governance system and a little corporate housekeeping can avoid larger messes down the road.

Details: The event is from 8:30 to 10:30 am on Thursday, February 13, at Baker Botts (910 Louisiana St., 32nd Floor). Learn more.

February 18 — How She Got There: Women Leaders in Tech

Join General Assembly for an evening good conversation with a panel of females in tech. These inspirational women will share their stories on how they got to where they are today and share their insights into being a woman in business and tech.

Details: The event is from 6:30 to 9 pm on Tuesday, February 18, at GA Houston (1301 Fannin St, Floor 21). Learn more.

February 19 — Houston Angel Summit

Join the Houston Angel Network for its bi-annual summit. Attendees will learn the basics of angel investing as well as hear from experts on the topics of term sheets and tax implication of early stage investing. This event is open to accredited investors, HAN members and individuals from our partnership organizations. The price of attendance — $100 — will be applied to annual membership if attendees decide to join the Houston Angel Network.

Details: The event is from 9 am to 3 pm on Wednesday, February 19, at Liu Idea Lab for Innovation and Entrepreneurship (Cambridge Building at Rice University). Learn more.

February 20 — The Five W's of Holding Your First, First-in-Human Trial

Who, what, when, where and why to hold your first, first-in-human clinical trial? JLABS has tapped into experts in the field from Johnson & Johnson, CROs and agencies to help you answer these questions and more.

Details: The event is from 11:30 am to 2 pm on Thursday, February 20, at JLABS @ TMC (2450 Holcombe Blvd.). Learn more.

February 20 — Bunker Brews Houston: How to be Mentored in Your Business

Lots of entrepreneurs fail to seek out mentors, and struggle in silence and isolation because of it. Some will find great mentors, but fail to recognize the unspoken rules of the road to acquire, activate, and maintain a mentor-mentee relationship. Hear from some great local mentors of business owners.

Details: The event is from 6 to 8 pm on Thursday, February 20, at MassChallenge (1313 Main St., Suite 210). Learn more.

February 20 — Rising Stars in Houston Health Tech

Join General Assembly for an epic night with some of the Houston's most inspiring healthtech founders and leaders. In a candid discussion, they'll share their stories and insights.

Details: The event is from 6:30 to 9 pm on Thursday, February 20, at GA Houston (1301 Fannin St, Floor 21). Learn more.

February 24 — Made in Houston: Celebrating Black History Month

In honor of Black History Month, General Assembly has organized an evening with some of Houston's legendary innovators and creators. Each speaker will share their tips and tricks on how to create a unique product, service or brand that's pushing the boundaries while sharing their journey.

Details: The event is from 6:30 to 9 pm on Monday, February 24, at GA Houston (1301 Fannin St, Floor 21). Learn more.

February 25 — The Cannon Lunch & Learn: Show me the Money

As an early stage company, raising capital is or will be a significant part of your efforts and can present major challenges. Preparation and an understanding of what drives value is crucial to attracting investors. Join Cannon partner, Baker Tilly, as they provide an overview of the capital raise process and highlight key factors to consider when preparing to raise capital.

Details: The event is from 11:30 am to 1 pm on Tuesday, February 25, at The Cannon (1334 Brittmoore Road). Learn more.

Vivante Health, which uses technology and at-home testing to help users treat chronic digestive health issues, has raised $5.8 million. Getty Images

Digital health startup based in Houston closes $5.8 million round

Money moves

A Houston health technology startup that uses digital solutions and on-demand support to help its users with digestive health has closed a Series A round of funding.

Vivante Health raised $5.8 million in a series A1 round, according to a news release. The round was led by California-based Lifeforce Capital and Athens, Greece-based Big Pi Ventures. Additionally, NFP Ventures, FCA Venture Partners, and Longmont Capital contributed to the round.

"We knew we were onto something when the market responded so positively," says Dr. Kimon Angelides, Vivante Health founder and CEO, in the release, "but support from esteemed, experienced and successful firms like Lifeforce and Big Pi, and the continued strong support from our initial investor partners, give us a very encouraging boost of confidence as we carry out our vision and further develop the GIThrive platform."

With the fresh funds, Vivante will continue to develop its GI health platform, GIThrive. The digital tool has an at-home microbiome test kit for users, as well as a breath tester that monitors food sensitivities. GIThrive also connects users to on-demand support from nutritionists and experts on the GIThrive app.

The startup's Houston headquarters is based out of the Johnson & Johnson Innovation Center, JLabs@TMC, but has offices in Nashville, Chicago, and Athens. Angelides, who honors his Greek heritage by spending a fair about of time in Greece, says in the release how important the Big Pi investment is for him.

"This partnership with Big Pi, a tech-based investment firm who's driven by the desire to support Greek talent, makes perfect sense. What's more, we have partnered with a team who themselves have been very successful entrepreneurs," says Angelides in the release.

Angelides, who has founded three other health tech companies, impressed Big Pi with his entrepreneurial track record and nationwide team

"This is one of those rare investments where the financial upside goes hand in hand with the prospect of radically improving the lives of millions of people across the globe," says Marco Veremis, investment partner with Big Pi, in the release.

Lifeforce Capital has a portfolio of software startups, including Aspire, Cricket Health, Notable Labs, One Medical, and Second Genome, per the news release, and the VC firm is excited for their new addition.

"We were immediately struck by Kim's entrepreneurial passion and big vision," says Sander Duncan, general partner with Lifeforce Capital, in the release. "We are thrilled to work with the Vivante team to build the first platform tackling digestive disease for millions of suffering patients."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.